Mobia Medical, Inc.

424B4 priced

Price $15.00 · 10,000,000 shares · Gross proceeds $139,500,000

Mobia Medical, Inc. is conducting its initial public offering (IPO) by issuing 10,000,000 shares of common stock at $15.00 per share, with proceeds of $139.5 million. The shares will be listed on Nasdaq under the symbol 'MOBI.' The company, an emerging growth company, highlights its FDA-approved Vivistim Paired Vagus Nerve Stimulation System for chronic ischemic stroke recovery. The offering includes underwriters such as BofA Securities, J.P. Morgan, and Goldman Sachs & Co. LLC, with an option for underwriters to purchase additional shares.

EFFECT effective

Mobia Medical, Inc. has received effectiveness for its Form S-1 registration statement, enabling the上市 of its common stock on The Nasdaq Stock Market LLC. This follows a previous 8-A12B filing that initiated the registration process for securities under Section 12(b) of the Securities Exchange Act. The current filing incorporates the prospectus details from the S-1 registration, which was initially filed on April 17, 2026.

8-A12B effective

Mobia Medical, Inc. filed Form 8-A12B to register its common stock, $0.01 par value, on The Nasdaq Stock Market LLC. The registration references the company's previously filed Registration Statement on Form S-1 (File No. 333-295160) and incorporates its prospectus by reference. The filing indicates the company's intent to transition from a Regulation A offering (CERT) to a traditional SEC registration under Section 12(b).

CERT inactive

Mobia Medical, Inc. is conducting an initial public offering (IPO) of 10,000,000 shares of common stock, with an expected price range of $14.00 to $16.00 per share. The company aims to list on the Nasdaq Global Select Market under the ticker symbol 'MOBI.' The offering includes underwriter options for additional shares and highlights risks related to market adoption, regulatory compliance, and dependence on key personnel. The filing reflects updates to previously disclosed information, though specific changes are obscured by formatting issues in the provided text.

S-1/A amended

Range $14.00 to $16.00 · 10,000,000 shares

Mobia Medical, Inc. is conducting its initial public offering (IPO) to raise capital by issuing 10,000,000 shares of common stock at an expected price range of $14.00 to $16.00 per share. The company, which develops medical devices for chronic stroke recovery, has developed the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, the first FDA-approved solution for ischemic stroke survivors with upper extremity impairments. The offering highlights its position as an emerging growth company and smaller reporting company, with shares expected to trade on Nasdaq under the symbol 'MOBI.' The filing emphasizes the unmet need in chronic stroke recovery and the potential market opportunity, citing estimates of over $30 billion in initial market opportunity.

S-1/A amended

Mobia Medical, Inc. is conducting its initial public offering (IPO) of common stock, aiming to raise capital to advance its chronic stroke recovery solutions. The company's Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the first FDA-approved treatment for chronic ischemic stroke survivors with upper extremity impairments. The offering includes a public price range, underwriter details, and plans for Nasdaq listing. The company emphasizes its position as an emerging growth company with a focus on addressing a significant unmet need in stroke recovery.

S-1 filed

Mobia Medical, Inc. is conducting its initial public offering (IPO) to raise capital through the sale of common stock. The company develops medical devices for chronic stroke recovery, with its Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System being the first FDA-approved solution for ischemic stroke survivors with upper extremity impairments. The IPO aims to accelerate growth, expand market reach, and fund further research and development. The shares are expected to trade on a specified exchange under the symbol 'MOBI' following the offering.

DRS/A amended

Mobia Medical, Inc. is preparing for its initial public offering (IPO) with Amendment No. 2 to its draft registration statement, filed confidentially with the SEC on March 24, 2026. The company aims to raise capital through the sale of common stock, with an expected offering price range and anticipated trading on a specified exchange. The filing highlights the company's proprietary Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, the first FDA-approved solution for chronic ischemic stroke survivors with upper extremity impairments. The filing emphasizes clinical data demonstrating efficacy in restoring motor function, along with a focus on market growth and regulatory milestones.

DRS/A amended

MicroTransponder, Inc. filed an amended draft registration statement (DRS/A) on March 11, 2026, updating its initial public offering (IPO) details. The filing reflects a name change to Mobia Medical, Inc., with updated corporate information, underwriters, and legal counsel. The amendment remains confidential and has not been publicly filed with the SEC.

DRS filed

MicroTransponder, Inc. is conducting its initial public offering (IPO) to raise capital, with a focus on its FDA-approved Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System for chronic ischemic stroke recovery. The company, an emerging growth company, aims to commercialize its medical device targeting motor impairments in stroke survivors. The IPO involves offering shares of common stock, with underwriters including BofA Securities, J.P. Morgan, and Goldman Sachs & Co. LLC. The filing highlights risks related to regulatory approvals, market competition, and reliance on its proprietary technology.